A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC) Meeting Abstract


Authors: Tew, W. P.; Sill, M.; McMeekin, D. S.; Secord, A. A.; Bonebrake, A. J.; Schilder, J.; Stuckey, A.; Rice, L.; Tewari, K. S.; Aghajanian, C.
Abstract Title: A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC)
Meeting Title: 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 32
Issue: 15 Suppl.
Meeting Dates: 2014 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2014-05-20
Language: English
ACCESSION: WOS:000358613203530
PROVIDER: wos
Notes: Meeting Abstract: 5546 -- Source: Wos
MSK Authors
  1. William P Tew
    114 Tew
Related MSK Work